## Procedure file

4.20.04 Pharmaceutical products and industry

## Basic information DEA - Delegated acts procedure Labelling requirements for unauthorised investigational and unauthorised auxiliary medicinal products for human use Supplementing 2012/0192(COD) Subject 4.20.02 Medical research 4.20.02.06 Clinical practice and experiments

| Key players         |  |            |           |
|---------------------|--|------------|-----------|
| European Parliament | Committee responsible  ENVI Environment, Public Health and Food Safety | Rapporteur | Appointed |

| Key events |   |              |  |  |
|------------|---|--------------|--|--|
| 06/09/2022 | Non-legislative basic document published              | C(2022)06240 |  |  |
| 06/09/2022 | Initial period for examining delegated act 2 month(s) |              |  |  |
| 14/09/2022 | Committee referral announced in<br>Parliament         |              |  |  |
| 15/11/2022 | Delegated act not objected by Parliament              |              |  |  |

| Technical information      |   |  |  |
|----------------------------|---|--|--|
| Procedure reference        | 2022/2819(DEA)  |  |  |
| Procedure type             | DEA - Delegated acts procedure                        |  |  |
| Procedure subtype          | Examination of delegated act                          |  |  |
| Stage reached in procedure | Procedure completed - delegated act enters into force |  |  |
| Committee dossier          | ENVI/9/10019  |  |  |

| Documentation gateway          |              |            |    |  |  |  |
|--------------------------------|--------------|------------|----|--|--|--|
| Non-legislative basic document | C(2022)06240 | 06/09/2022 | EC |  |  |  |